BAG3 gene silencing sensitizes leukemic cells to Bortezomib‐induced apoptosis
- 25 December 2008
- journal article
- Published by Wiley in FEBS Letters
- Vol. 583 (2), 401-406
- https://doi.org/10.1016/j.febslet.2008.12.032
Abstract
Proteasome inhibition has emerged as a powerful option for the treatment of a number of malignancies including leukemias. However, Bortezomib showed limited single-agent activity for patients with leukemia. Here, we report for the first time that Bortezomib up-regulated a novel antiapoptotic protein, BAG3, in human leukemic cells. BAG3 gene knockdown with shRNA greatly potentiated the generation of apoptosis by Bortezomib in leukemia cells. Furthermore, BAG3 silencing enhanced the antitumor activity of Bortezomib dramatically in a nude mouse model. Our results indicate that knocking down BAG3 gene is a promising new approach to enhance the therapeutic potency of Bortezomib in leukemiaThis publication has 33 references indexed in Scilit:
- Proteasome Inhibitors in Cancer Therapy: Lessons from the First DecadeClinical Cancer Research, 2008
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesBlood, 2005
- Proteasome Inhibition As a Novel Therapeutic Target in Human CancerJournal of Clinical Oncology, 2005
- Phase I Study of Bortezomib in Refractory or Relapsed Acute LeukemiasClinical Cancer Research, 2004
- The development of proteasome inhibitors as anticancer drugsCancer Cell, 2004
- What's in the ‘BAG’? – a functional domain analysis of the BAG-family proteinsCancer Letters, 2002
- Development of the Proteasome Inhibitor PS‐341The Oncologist, 2002
- Proteasome inhibition in cancer: Development of PS-341Seminars in Oncology, 2001
- CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-γ and Hsp70/Hsc70Oncogene, 2000
- The ubiquitin-proteasome proteolytic pathwayCell, 1994